Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Greg Yothers

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Toward progression-free survival as a primary end point in advanced colorectal cancerGreg Yothers
Journal of Statistical Planning and Inference|July 14, 2015
Simultaneous Confidence Band for the Difference of Segmented Linear ModelsGreg Yothers, Allan R Sampson
Journal of the National Cancer Institute|December 3, 2010
Multiagent regimens for metastatic colorectal cancer: if some is good, more must be betterCarmen Allegra, Thomas George, Greg Yothers
JAMA Oncology|October 27, 2015
Cancer Hallmark-Based Gene Sets and Personalized Medicine for Patients With Stage II Colon CancerGreg Yothers, Nan Song, Thomas J George
Journal of Oncology Practice|September 28, 2010
Prevalence of burnout in the u.s. Oncology community: results of a 2003 surveyCarmen J Allegra, Ray Hall, Greg Yothers
Clinical Advances in Hematology & Oncology : H&O|November 23, 2006
Randomization in Phase II Clinical TrialsGreg Yothers, Samuel Wieand, Emil J Freireich
Current Colorectal Cancer Reports|September 1, 2015
Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical TrialsThomas J George, Carmen J Allegra, Greg Yothers
Clinical Trials (London, England)|July 20, 2012
A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trialsMichael W Sill, Larry Rubinstein, Samuel Litwin, et al.
Lifetime Data Analysis|January 22, 2008
Exploring and validating surrogate endpoints in colorectal cancerTomasz Burzykowski, Marc Buyse, Greg Yothers, et al.
Cancer Investigation|September 18, 2008
FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancerSaima Sharif, Michael J O'Connell, Greg Yothers, et al.
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Toward progression-free survival as a primary end point in advanced colorectal cancerGreg Yothers
Journal of Statistical Planning and Inference|July 14, 2015
Simultaneous Confidence Band for the Difference of Segmented Linear ModelsGreg Yothers, Allan R Sampson
Journal of the National Cancer Institute|December 3, 2010
Multiagent regimens for metastatic colorectal cancer: if some is good, more must be betterCarmen Allegra, Thomas George, Greg Yothers
JAMA Oncology|October 27, 2015
Cancer Hallmark-Based Gene Sets and Personalized Medicine for Patients With Stage II Colon CancerGreg Yothers, Nan Song, Thomas J George
Journal of Oncology Practice|September 28, 2010
Prevalence of burnout in the u.s. Oncology community: results of a 2003 surveyCarmen J Allegra, Ray Hall, Greg Yothers
Clinical Advances in Hematology & Oncology : H&O|November 23, 2006
Randomization in Phase II Clinical TrialsGreg Yothers, Samuel Wieand, Emil J Freireich
Current Colorectal Cancer Reports|September 1, 2015
Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical TrialsThomas J George, Carmen J Allegra, Greg Yothers
Clinical Trials (London, England)|July 20, 2012
A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trialsMichael W Sill, Larry Rubinstein, Samuel Litwin, et al.
Lifetime Data Analysis|January 22, 2008
Exploring and validating surrogate endpoints in colorectal cancerTomasz Burzykowski, Marc Buyse, Greg Yothers, et al.
Cancer Investigation|September 18, 2008
FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancerSaima Sharif, Michael J O'Connell, Greg Yothers, et al.
Pageof 12